Triomics, a company advancing generative AI models to streamline workflows for cancer centers secures $15million in funding. Lightspeed, Y Combinator, General Catalyst, and Nexus Venture Partners were among the backers.
The money will be used by the business to grow both its operations and growth initiatives. Triomics, led by Sarim Khan, the CEO, and Hrituraj Singh, the CTO, creates generative AI models specifically tailored for oncology (OncoLLMTM) and uses case-specific software to assist cancer providers in processing large amounts of free-text health record data, matching patients to clinical trials, enhancing quality-of-care operations, and providing precision oncology.
Read also – [Funding News] IL-based FleetPulse Secures $11Million in Seed Funding
With the help of its OncoLLMTM, proprietary software that interfaces with EHRs in healthcare systems may do a variety of administrative and clinical functions. Triomics Prism, for instance, helps in patient-trial matching by using prescreening to identify clinical trials that are pertinent to cancer patients who have scheduled visits.
EHR data is curated by Triomics Harmony to facilitate precision oncology, cohort analysis, and quality reporting. Next, Triomics intends to create software that supports more use cases and release more data on the effectiveness of OncoLLM in a range of patient demographics and contexts.
Hrituraj Singh said: “Our investments in our core areas of focus have been deliberate. We have successfully merged expertise in two complex functional areas: our AI researchers, who are specialized in customizing language models to specific domains, and our clinical staff, who have decades of oncology-specific experience. As a result, our software can complement the strengths of these advanced models while also proactively addressing potential flaws, all with the intricacies of cancer research and care in mind.”
About Triomics
Triomics is working with cancer centres to employ Generative AI to leverage their health record data and cut down on human labour in oncology research and treatment.
